Analysts See $-0.67 EPS for Acceleron Pharma Inc. (XLRN)

October 13, 2018 - By Winifred Garcia

Acceleron Pharma Inc. (NASDAQ:XLRN) LogoInvestors sentiment increased to 1.47 in 2018 Q2. Its up 0.20, from 1.27 in 2018Q1. It is positive, as 17 investors sold Acceleron Pharma Inc. shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 38.98 million shares or 1.76% more from 38.30 million shares in 2018Q1 were reported.
Tiaa Cref Investment Ltd Limited Liability Company holds 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 102,798 shares. Metropolitan Life Ins New York invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). State Of Wisconsin Invest Board has invested 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN). Savings Bank Of America Corp De has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). 250 were reported by Daiwa Securities. Baker Bros Lp accumulated 163,900 shares or 0.06% of the stock. Envestnet Asset Mngmt reported 506 shares or 0% of all its holdings. 795,043 are held by Westfield Cap Management Co Lp. Moreover, Manufacturers Life Ins The has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Svcs Automobile Association holds 0.04% in Acceleron Pharma Inc. (NASDAQ:XLRN) or 73,493 shares. Birchview Limited Partnership holds 0.4% or 12,000 shares in its portfolio. Proshare Advsrs Ltd accumulated 24,333 shares. Sei Invests Company holds 0% or 300 shares in its portfolio. Wells Fargo And Mn reported 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Citigroup has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN).

Since June 29, 2018, it had 0 insider purchases, and 2 insider sales for $1.88 million activity.

Analysts expect Acceleron Pharma Inc. (NASDAQ:XLRN) to report $-0.67 EPS on November, 6.They anticipate $0.02 EPS change or 3.08 % from last quarter’s $-0.65 EPS. After having $-0.63 EPS previously, Acceleron Pharma Inc.’s analysts see 6.35 % EPS growth. The stock increased 2.83% or $1.37 during the last trading session, reaching $49.86. About 236,518 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 31.27% since October 14, 2017 and is uptrending. It has outperformed by 15.65% the S&P500.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 5 analysts covering Acceleron Pharma (NASDAQ:XLRN), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Acceleron Pharma had 7 analyst reports since May 22, 2018 according to SRatingsIntel. Goldman Sachs upgraded the stock to “Neutral” rating in Friday, June 29 report. The stock has “Hold” rating by Oppenheimer on Tuesday, May 22. Morgan Stanley reinitiated it with “Equal-Weight” rating and $55 target in Monday, September 10 report. The company was downgraded on Friday, July 13 by Morgan Stanley. The firm earned “Neutral” rating on Tuesday, July 10 by PiperJaffray. The company was maintained on Friday, June 29 by Credit Suisse. PiperJaffray upgraded Acceleron Pharma Inc. (NASDAQ:XLRN) rating on Tuesday, September 18. PiperJaffray has “Overweight” rating and $75 target.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $2.29 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The company's therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

More recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: which released: “Analyst: Acceleron’s Blood Disorder Candidate Luspatercept Has Blockbuster Potential” on September 18, 2018. Also published the news titled: “3 Top Small-Cap Stocks to Buy Right Now” on October 04, 2018.‘s news article titled: “Key events next week – healthcare” with publication date: September 28, 2018 was also an interesting one.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.